Aker BioMarine has secured a new Superba Krill Oil business. On a full-year
run-rate basis, this business would rank among the company's largest customer
relationships. Deliveries on the first purchase order commence in Q4 2026.
"I am very pleased to secure another significant win for Superba Krill Oil. Wins
of this scale, alongside continued momentum across our broader customer base,
are what drive sustainable long-term growth," said Matts Johansen, CEO of Aker
BioMarine.
For further information, please contact
Christopher Robin Vinter, SVP Finance
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation article 7 and is subject to the disclosure requirements
pursuant to MAR article 17 and Section 5-12 the Norwegian Securities Trading
Act. This stock exchange announcement was published by Christopher Vinter, SVP
Finance, Aker BioMarine ASA, on July 10, 2026, 06:55 CET.
About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+,
as well as the consumer brand, Kori Krill. The innovative approach also extends
into the spin-offs AION (reduce and recycle plastic waste across industries) and
Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock
Exchange (AKBM). More information is available at www.akerbiomarine.com.
information is available at www.akerbiomarine.com.\